Correlated Drug Terms (31)

---

	Name (Synonyms)	Correlation
drug2046	PWV Wiki	0.26
drug1075	FMD Wiki	0.26
drug210	Angiotensin converting enzyme inhibitor Wiki	0.26
drug2906	Thiazide or Thiazide-like diuretics Wiki	0.26
drug780	Cospherunate/Azythromycine Wiki	0.26
drug3256	echocardiogram 2D Wiki	0.26
drug1938	Nutritional support system (NSS) Wiki	0.26
drug781	Cospherunate/Phytomedicine/Azythromycien Wiki	0.26
drug792	Covid19 Wiki	0.26
drug59	ABPM Wiki	0.26
drug876	Dexmethylphenidate Wiki	0.26
drug66	ACEI/ARB Wiki	0.26
drug867	Detection of anti-COVID-19 antibody level Wiki	0.26
drug1333	Hydroxycloroquine and Azythromycine Wiki	0.26
drug2373	Rarefaction Wiki	0.26
drug211	Angiotensin receptor blocker Wiki	0.26
drug598	Calcium Channel Blockers Wiki	0.26
drug1902	Non-ACEI/ARB Wiki	0.26
drug340	BI 1569912 Wiki	0.26
drug2884	The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki	0.26
drug749	Control-EDI Wiki	0.26
drug1000	Enhanced Chronic Disease Self-management program Wiki	0.26
drug65	ACEI Wiki	0.26
drug1460	Intervention-EDI and health coaching Wiki	0.26
drug944	ECG Wiki	0.18
drug87	ARB Wiki	0.18
drug63	ACE inhibitor Wiki	0.15
drug1885	No Intervention Wiki	0.15
drug681	Clinical data Wiki	0.15
drug740	Control Wiki	0.09
drug2122	Placebo Wiki	0.01

Correlated MeSH Terms (25)

---

	Name (Synonyms)	Correlation
D006973	Hypertension NIH	1.00
D006976	Hypertension, Pulmonary NIH	0.37
D001997	Bronchopulmonary Dysplasia NIH	0.26
D008595	Menorrhagia NIH	0.26
D006929	Hyperaldosteronism NIH	0.26
D054559	Hyperphosphatemia NIH	0.26
D004314	Down Syndrome NIH	0.26
D000309	Adrenal Insufficiency NIH	0.26
D007008	Hypokalemia NIH	0.26
D009080	Mucocutaneous Lymph Node Syndrome NIH	0.18
D014552	Urinary Tract Infections NIH	0.18
D002908	Chronic Disease NIH	0.15
D001289	Attention Deficit Disorder with Hyperactivity NIH	0.13
D006470	Hemorrhage NIH	0.13
D051436	Renal Insufficiency, Chronic NIH	0.12
D002318	Cardiovascular Diseases NIH	0.10
D007674	Kidney Diseases NIH	0.09
D020141	Hemostatic Disorders NIH	0.07
D001778	Blood Coagulation Disorders NIH	0.07
D004194	Disease NIH	0.04
D013577	Syndrome NIH	0.03
D003141	Communicable Diseases NIH	0.02
D018352	Coronavirus Infections NIH	0.02
D007239	Infection NIH	0.01
D045169	Severe Acute Respiratory Syndrome NIH	0.01

Correlated HPO Terms (11)

---

	Name (Synonyms)	Correlation
HP:0002092	Pulmonary arterial hypertension HPO	0.37
HP:0002905	Hyperphosphatemia HPO	0.26
HP:0002900	Hypokalemia HPO	0.26
HP:0000846	Adrenal insufficiency HPO	0.26
HP:0000132	Menorrhagia HPO	0.26
HP:0000859	Hyperaldosteronism HPO	0.26
HP:0007018	Attention deficit hyperactivity disorder HPO	0.13
HP:0012622	Chronic kidney disease HPO	0.12
HP:0001626	Abnormality of the cardiovascular system HPO	0.10
HP:0000077	Abnormality of the kidney HPO	0.09
HP:0001928	Abnormality of coagulation HPO	0.07

Primary Outcomes

Description: Changes in systolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.

Measure: Change in Systolic Blood Pressure between baseline and 12 months

Time: Baseline, 12 months

---

Secondary Outcomes

Description: Changes in diastolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.

Measure: Change in Diastolic Blood Pressure between baseline and 12 months

Time: Baseline, 12 months

---

Description: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.

Measure: Slope of systolic BP between baseline and 12 months using all available BP values

Time: Baseline up to 12 months

---

Description: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.

Measure: Slope of diastolic BP between baseline and 12 months using all available BP values

Time: Baseline up to 12 months

---

Description: This is a 28-item questionnaire measuring objective CKD disease knowledge and includes questions about goals, cardiovascular risk, and anti-hypertensive medications. Patients will answer the questions with a yes or no answer and their score will be based on how many responses were correct. This number will be converted to a percentage.

Measure: CKD knowledge measured by the Kidney Knowledge Survey (KiKS)

Time: Baseline up to 12 months

---

Description: This is a 13-item measure with the answers on a Likert scale of 1 (not at all sure) to 4 (extremely sure). The higher the score the higher the self-efficacy, with a range from 13-52.

Measure: Medication Adherence Self-Efficacy Scale-Revised (MASES-R)

Time: Baseline up to 12 months

---

Description: This scale is to quantify adherence to pharmacological treatments by means of 8 items. Patients will answer yes or no to these items, where a no response = 1 point and a yes response = 0 points. Levels of adherence are based on the following scores: 3-8 = low adherence; 1-2 = medium adherence; 0 = high adherence.

Measure: Morisky Medication Adherence Scale (MMAS - 8)

Time: Baseline up to 12 months

---

Description: Length of time provider spends with the patient. This will be compared between the intervention group and control group.

Measure: Visit Time with provider

Time: Enrollment visit (baseline)

---

Description: Length of time between patient check-in and check-out. This will be compared between the intervention group and control group.

Measure: Total time in clinic

Time: Enrollment visit (baseline)

---

Description: This contains a 17-item questionnaire in which the participants select scores from 1-7 or does not apply. A number of 1 = not at all and a score of 7 = considered very true, and zero = not applicable.

Measure: Patient Motivation by the Treatment Self-Regulation Questionnaire scale (TSRQ)

Time: Baseline up to 12 months

---

Description: This is a 15-item questionnaire that assesses the quality of physician to patient communication completed by the patients. There are 5 answers to choose from; poor, fair, good, very good, and excellent. The Score range is 1-5, where 1 means negative perception of communication and 5 means positive perception of communication.

Measure: Satisfaction with CKD care based on Communication Assessment Tool (CAT)

Time: Baseline up to 12 months

---

Description: This is a 21-item questionnaire that is completed by the patients, and select from the the 4 choices: very strongly agree, strongly agree, agree, and neutral/disagree. Each answer is worth one point on a Likert scale with a higher score meaning more satisfied.

Measure: Satisfaction with CKD care based on Consultation Care Measure (CCM)

Time: Baseline up to 12 months

---

Description: During health coach phone calls, participants will be asked 37 questions about their perceptions of the health coach program, including how much their participation in CHECK-D helped participants change various behaviors. Participant responses will be used to examine various measures of reliability and validity during the analyses of data acquired though this survey.

Measure: Perceptions of health coaching for the intervention group

Time: Baseline up to 12 months

---

Description: The EMR will be reviewed to evaluate the patients medication refills for adherence.

Measure: Medication adherence from the electronic medical record (EMR)

Time: Baseline up to 12 months

---

Description: This is an 8-item scale regarding self-efficacy where each statement is rated on the level of agreement from 1-5. 1 is disagree and 5 is agree.

Measure: Self-efficacy for disease self-management based on The Perceived Kidney/Dialysis Self-Management Scale (PKDSMS)

Time: Baseline up to 12 months

---

Description: This is a 5-item survey about knowledge and behaviors regarding sodium in the diet.

Measure: Self-reported Blood Pressure-Related Behaviors Survey

Time: Baseline up to 12 months

---

Description: Provider adoption will be measured by the percentage of enrolled patients whose providers used the EDI with them during their visit. Data will be collected by EMR query and a 1-item question in the patient survey.

Measure: Provider Adoption based on EMR query and patient survey

Time: Baseline

---

Description: Provider fidelity will be measured by the percentage of enrolled patients in the intervention clinics whose providers entered 1-2 patient specific goals in the EDI. This will be collected through EMR query.

Measure: Provider Fidelity measured by EMR query

Time: Baseline

---

Description: Provider perception of usefulness will be measured by a survey of 2-3 questions about how useful they thought it was.

Measure: Provider Perception of Usefulness by provider survey

Time: Baseline up to 12 months

---

Description: Change in Serum Creatinine between baseline and 12-months

Measure: Change in serum creatinine

Time: Baseline, 12 months

---

Measure: Change in urine protein-creatinine ratio

Time: Baseline, 12 months

---

Measure: Change in estimated glomerular filtration rate (eGFR)

Time: Baseline, 12 months

---

Primary Outcomes

Description: The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.

Measure: Occupancy rate in the intensive care unit (ICU)

Time: up to 28 days

---

Description: The number of patients requiring mechanical ventilation.

Measure: Mechanical Ventilation

Time: up to 28 days

---

Description: The number of patients who died of 2019-nCoV infection.

Measure: Death

Time: up to 28 days

---

Secondary Outcomes

Description: The number of died 2019-nCoV infected patients from any cause.

Measure: All cause mortality

Time: up to 28 days

---

Description: Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death.

Measure: Time from onset of symptoms to main outcome and its components

Time: up to 28 days

---

Description: Time to Clinical Recovery

Measure: Time to Clinical Recovery

Time: up to 28 days

---

Primary Outcomes

Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

---

Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

---

Measure: Elimination rate constant (ke) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

---

Measure: Half-life (t1/2) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

---

Measure: Absorption rate constant (ka) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

---

Measure: AUC (area under the curve) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

---

Measure: Maximum concentration (Cmax) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

---

Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

---

Primary Outcomes

Description: mortality in 28-day

Measure: Rate of Death

Time: From date of admission until the date of death from any cause, up to 60 days

---

Secondary Outcomes

Description: evaluate the severity of pneumonia according to CT scans and clinical manifestation

Measure: the severity of pneumonia

Time: From date of admission until the date of discharge or death from any cause, up to 60 days

---

Other Outcomes

Description: days from admission to discharge or death

Measure: the length of hospital stay

Time: From date of admission until the date of discharge or death from any cause, up to 60 days

---

Primary Outcomes

Description: Time from randomization to the first occurrence of any of the clinical events above

Measure: Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)

Time: 12 months

---

Secondary Outcomes

Description: Time from randomization to the first occurrence of above

Measure: Number of Covid-19 positive participants who die

Time: 12 months

---

Description: Time from randomization to the first occurrence of above

Measure: Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)

Time: 12 months

---

Description: Time from randomization to the first occurrence of above

Measure: Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)

Time: 12 months

---

Description: Time from randomization to the first occurrence of above

Measure: Number of SARS-CoV-2 positive participants

Time: 12 months

---

Measure: Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization

Time: 12 months

---

Description: Performed in a random sub-sample of the cohort (both study arms)

Measure: 24 hour mean systolic BP (mmHg) on ambulatory BP monitoring

Time: 12 months

---

Description: Time from randomization to the first occurrence of above

Measure: All-cause mortality

Time: 12 months

---

Primary Outcomes

Description: Using anamnestic data collected from the health record of the hospital or of the general practitioner, we will count the number of COVID-19 patients enrolled that were treated with ACE Inhibitors or ARB.

Measure: Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents

Time: 3 months

---

Description: This study want to observe whether the assumption of antihypertensive ACE inhibitors or ARB increases the severity of the clinical manifestation of COVID19

Measure: Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents

Time: 3 months

---

Secondary Outcomes

Description: Collecting selected data from the health record and hospital charts of the patients we will assess whether among the recorded parameters there are any that can predict COVID19 prevalence and severity

Measure: Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity

Time: 3 months

---

Primary Outcomes

Description: BP one week before COVID-19 infection and 3 weeks follow-up after COVID-19 onset

Measure: BP (hypertensive efficacy)

Time: 4 weeks

---

Secondary Outcomes

Description: features of disease course: number of patients and duration of fever (above 37.2C), duration of cough (days), duration of throat pain (days), headache (days), nausea or vomiting (days), diarrhea (days), myalgia or arthalgia (days), and numder of patients who need hospital and intensive care unit

Measure: COVID-19 course

Time: 3 weeks

---

Primary Outcomes

Description: Death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

Measure: Adverse events

Time: through study completion, an average of 2 weeks

---

Secondary Outcomes

Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints

Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

Time: through study completion, an average of 2 weeks

---

Description: Ventilation during hospitalization

Measure: Ventilation during hospitalization

Time: through study completion, an average of 2 weeks

---

Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints

Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

Time: prolonged follow up, through study completion, an average of one year

---

Primary Outcomes

Description: Prevalence of a previous treatment by angiotensin converting enzyme inhibitors in patients with and without confirmed Covid-19 pneumonia.

Measure: Prior treatment by ACEi

Time: at admission to hospital

---

Description: Prevalence of a previous treatment by angiotensin II type 1-receptor blockers in patients with and without confirmed Covid-19 pneumonia.

Measure: Prior treatment by ARB

Time: at admission to hospital

---

Secondary Outcomes

Description: Association between COVID-19 infection status and other baseline characteristics and comorbidities (age, sex, history of hypertension, chronic heart disease, diabetes mellitus, COPD, asthma, obesity, allergies)

Measure: Baseline characteristics and comorbidities

Time: at admission to hospital

---

Description: Association between previous treatment by ACEi and ARBs and clinical course of COVID-19 (one-month mortality, hospitalization in intensive care unit, duration of hospital stay, early discharge to home)

Measure: Major Clinical Adverse Events

Time: One month follow-up

---

Primary Outcomes

Description: Ambulatory Blood Pressure Monitoring systolic blood pressure

Measure: ABPM systolic blood pressure

Time: 24 hours (all day and night)

---

Secondary Outcomes

Description: Ambulatory Blood Pressure Monitoring diastolic blood pressure

Measure: 24-hr ABPM DBP

Time: 24 hours (all day and night)

---

Description: Day Ambulatory Blood Pressure Monitoring systolic blood pressure

Measure: day ABPM SBP

Time: 8am to 8pm

---

Description: Day Ambulatory Blood Pressure Monitoring diastolic blood pressure

Measure: day ABPM DBP

Time: 8am to 8pm

---

Description: Night Ambulatory Blood Pressure Monitoring systolic blood pressure

Measure: night ABPM SBP

Time: 8pm to 8am

---

Description: Night Ambulatory Blood Pressure Monitoring diastolic blood pressure

Measure: night ABPM DBP

Time: 8pm to 8am

---

Description: The fall in pressure, called the "dip", is defined as the difference between daytime mean systolic pressure and nighttime mean systolic pressure expressed as a percentage of the day value

Measure: dipping status

Time: 24 hours (all day and night)

---

Description: he morning surge was defined as the difference between the mean systolic blood pressure during the 2 hours after waking and arising minus the mean systolic blood pressure during the hour that included the lowest blood pressure during sleep.

Measure: morning surge

Time: 24 hours (all day and night)

---

Description: 24 hour Ambulatory Blood Pressure Monitoring heart rate

Measure: 24 hour ABPM HR

Time: 24hr (all day and night)

---

Description: Day Ambulatory Blood Pressure Monitoring heart rate

Measure: day ABPM HR

Time: 8 am to 8 pm

---

Description: Night Ambulatory Blood Pressure Monitoring heart rate

Measure: night ABPM HR

Time: 8pm to 8 am

---

Primary Outcomes

Description: We will measure systolic blood pressure before and 6 months after the interventions

Measure: Systolic blood pressure

Time: Six months

---

Secondary Outcomes

Description: We will measure participants' weight in kilograms before and six months after the intervention

Measure: Mean weight change for intervention and control groups

Time: Six months

---

Description: Changes in dietary behavior will be monitored by using the Dietary Approaches to Stop Hypertension Accordance Score. Score ranges from 0 to 9. A low score represents a poor diet for hypertension control. The higher the score the more appropriate for hypertension control.

Measure: Level of adherence to the Dietary Approaches to Stop Hypertension (DASH) Diet

Time: Six months

---

Description: Using the results of the GPAQ median physical activity in MET-minutes per week will be calculated before the intervention as well as six months post intervention

Measure: Assessing physical activity levels using the Global Physical Activity Questionnaire (GPAQ)

Time: Six months

---

Description: Perceived self-efficacy scores will be calculated using a tool developed by K Lorig(Stanford University School of Medicine) for measuring self-efficacy in chronic disease management programs. Score ranges from 1 to 10. A higher score is better.

Measure: Self-Efficacy for Managing Chronic Diseases 6-item Scale

Time: Six months

---

Primary Outcomes

Description: To determine the prevalence of pulmonary hypertension and right ventricular load in patients with COVID-19 treated in intensive care unit evaluated by routine echocardiography.

Measure: Prevalence

Time: Day 1

---

Primary Outcomes

Description: For outpatient Veterans with a positive SARS-CoV-2 test (Aims 1.1 and 1.2), the primary outcome is a composite of time to all-cause hospitalization or all-cause mortality.

Measure: All-Cause-Hospitalization or All-Cause Mortality

Time: Through study completion (approximately July 31, 2020).

---

Description: For Veterans hospitalized with COVID-19 (Aims 2.1 and 2.2), the primary outcome is time to all-cause mortality.

Measure: All-Cause Mortality

Time: Through study completion (approximately July 31, 2020).

---

Secondary Outcomes

Description: For aims 1 and 2, a secondary outcome will be time to intensive care unit (ICU) admission.

Measure: ICU admission

Time: Through study completion (approximately July 31, 2020).

---

Description: For aims 1 and 2, a secondary outcome will be duration of hospitalization.

Measure: Duration of hospitalization

Time: Through study completion (approximately July 31, 2020).

---

Description: For aim 2, a secondary outcome will be time to mechanical ventilation.

Measure: Mechanical ventilation

Time: Through study completion (approximately July 31, 2020).

---

Description: For aim 2, a secondary outcome will be time to in-hospital dialysis.

Measure: Dialysis

Time: Through study completion (approximately July 31, 2020).

---

Other Outcomes

Description: Time to gastrointestinal bleed. This will be a negative control outcome.

Measure: Gastrointestinal bleed

Time: Through study completion (approximately July 31, 2020).

---

Description: Time to urinary tract infection. This will be a negative control outcome.

Measure: Urinary tract infection

Time: Through study completion (approximately July 31, 2020).

---

Primary Outcomes

Description: Left atrium volume index

Measure: • LA volume index

Time: 3 minutes

---

Description: Left ventricle telediastolic diameter

Measure: • LV telediastolic diameter

Time: 3 minutes

---

Description: Left ventricle telesystolic diameter

Measure: • LV telesystolic diameter

Time: 3 minutes

---

Description: Left ventricle posterior wall

Measure: • LV posterior wall

Time: 3 minutes

---

Description: Right atrium area

Measure: • RA area

Time: 3 minutes

---

Description: Right ventricle basal dimensión

Measure: • RV basal dimensión

Time: 3 minutes

---

Description: Right ventricle cavity dimensión

Measure: • RV mid cavity dimension;

Time: 3 minutes

---

Description: Right ventricle longitudinal dimension

Measure: • RV longitudinal dimension

Time: 3 minutes

---

Description: Distal, right ventricle outflow tract dimension at the distal or pulmonic valve level

Measure: • Distal, RV outflow tract dimension at the distal or pulmonic valve level

Time: 3 minutes

---

Description: Proximal right ventricle outflow tract dimension at the proximal subvalvular level

Measure: • Proximal RV outflow tract dimension at the proximal subvalvular level

Time: 3 minutes

---

Description: • Tricuspid annular plane systolic excursion

Measure: • TAPSE

Time: 3 minutes

---

Description: Right ventricle free Wall strain

Measure: • RV free Wall strain

Time: 3 minutes

---

Description: Inferior cava vein PW Doppler

Measure: • Inferior cava vein PW Doppler

Time: 3 minutes

---

Description: E wave mitral

Measure: • E wave mitral

Time: 3 minutes

---

Description: A wave mitral

Measure: • A wave mitral

Time: 3 minutes

---

Description: E wave /A wave mitral

Measure: • E wave /A wave mitral

Time: 3 minutes

---

Description: E-wave at mitral annulus

Measure: • E-wave at mitral annulus

Time: 3 minutes

---

Description: E-wave at mitral annulus / A-wave at the mitral annulus

Measure: • E-wave at mitral annulus / A-wave at the mitral annulus

Time: 3 minutes

---

Description: E wave/ E-wave at the mitral annulus

Measure: • E wave/ E-wave at the mitral annulus

Time: 3 minutes

---

Description: E tricuspid (E)

Measure: • E tricuspid (E)

Time: 3 minutes

---

Description: A triuspid (A)

Measure: • A tricuspid (A)

Time: 3 minutes

---

Description: E/A

Measure: • E/A

Time: 3 minutes

---

Description: Systolic pulmonary artery pressure

Measure: • Systolic pulmonary artery pressure

Time: 3 minutes

---

Description: E-wave at the tricuspid annulus

Measure: • E-wave at the tricuspid annulus

Time: 3 minutes

---

Description: Mean pulmonary artery pressure

Measure: • Mean pulmonary artery pressure

Time: 3 minutes

---

Description: Stroke volume

Measure: • Stroke volume

Time: 3 minutes

---

Description: Cardiac output

Measure: • Cardiac output

Time: 3 minutes

---

Primary Outcomes

Description: Fraction of oxygen-saturated hemoglobin relative to the patient's total blood hemoglobin, represented as a percentage. Measurement using the pulse oximeter of the multi-parameter vital signs monitor. Measurement units % SpO2.

Measure: Oxygen saturation

Time: 1 minute

---

Description: Balance between the production of heat by the body and its loss. Measurement using an infrared thermometer. Units of measure degrees centigrade.

Measure: Body temperature

Time: 30 seconds

---

Description: Force exerted by the blood against the walls of the vessels (arteries) as it is pumped by the heart. Measurement using the multi-parameter vital signs monitor. Units of measurement in mmHg. Obtain systolic and diastolic pressure.

Measure: Blood pressure

Time: 2 minutes

---

Description: Number of times the heart beats for a certain period of time, measured by the multi-parameter vital signs monitor. Units of measure beats per minute.

Measure: Heart rate

Time: 1 minute

---

Description: Number of breaths that a living being takes during a certain period of time, Count daily with the patient at rest the number of breaths for one minute each time the chest rises. Measured in breaths per minute.

Measure: Breathing frequency

Time: 1 minute

---

Description: Disruption of the organic functions of any living being. The existence of the death certificate will be reviewed daily. Categories: dead or alive.

Measure: Death

Time: 10 seconds

---

Description: Simultaneous knowledge, in the unity of time, of oneself (subject) and of the surrounding world (object), is the reflection of reality. It will be evaluated daily with the glasgow scale. Categories: 1.13-15 points. 2. 9-12 points. 3. 3-8 points.

Measure: Awareness

Time: 2 minutes

---

Description: Number of days that the patient remains hospitalized. It is reviewed daily if the patient has been discharged. Categories: 1.Hopitalized. 2. Released.

Measure: Hospital stay

Time: 10 seconds

---

Description: Rapid sequential evaluation of organic failures. Evaluate daily the qSOFA items and get your score. Measure in points.

Measure: qSOFA score

Time: 1 minute

---

Description: Clinically and study-based acquired need to open the airway in order to supply him with oxygen. Check daily if a cannula or tube was placed in the windpipe. Categories: 1.Progress to ventilation. 2. Does not progress to ventilation.

Measure: Progression to ventilation

Time: 10 seconds

---

Description: Need for a multidisciplinary team, for presenting an acute critical state, with the support of technological resources for monitoring, diagnosis and treatment. It is reviewed daily if the patient is directed to ICU. Categories: 1.Enter ICU. 2. You do not enter ICU.

Measure: Progression to Intensive Care Unit

Time: 10 seconds

---

Description: Any localized painful discomfort in the head. Evaluate and ask for pain by numbering it from 1-10, where 0 is the absence and 10 is the greatest intensity (Daily, 2 shifts, 21 days).

Measure: Cephalea

Time: 10 seconds

---

Description: Physical actions that you can take without pain or discomfort. Evaluate what movements and activities he tolerates (Daily, 2 shifts, 21 days). Categories: 1.Walk. 2.He can stand 3.Sit. 4.Postrate.

Measure: Activity level

Time: 10 seconds

---

Description: Body postures that are used to facilitate the examination of the patient, his treatment, the prevention of injuries due to immobility, and his comfort when he is bedridden. Observe the anatomical position in which he is found (Daily, 2 shifts, 21 days). Categories: 1. In the prone position. 2.In the supine position. 3.Fowler. 4.Semifowler. 5.Other

Measure: Anatomic position

Time: 10 seconds

---

Description: Evaluate the level of hydration of the hair (Daily, morning, 21 days). Categories: 1.Hydrated, shiny. 2.Opaque. 3.Very dull and dry.

Measure: Hair hydration

Time: 19 seconds

---

Description: Evaluate hair loss with the "pull sign" by pulling the hair without the intention of plucking, daily in the morning (Daily, morning, 21 days).Categories 1. <5 hairs on hand. 2. 5-10 hairs. 3.> 10 hairs.

Measure: Hair loss

Time: 20 seconds

---

Description: Targeted search for one or more asymptomatic sudden onset decalvary patches throughout the hair territory (Daily, morning, 21 days). Categories: 1. Without decalvary plates. 2. With regional decalvary plates. 3. Generalized alopecia areata.

Measure: Decalvary patches

Time: 10 seconds

---

Description: Inspect the scalp for lesions (Daily, morning, 21 days). Categories: 1.No injuries. 2. Flaking. 3.Erythema. 4.Infection. 5. Bleeding.

Measure: Scalp lesions

Time: 15 seconds

---

Description: Ask about itching of the scalp (Daily, morning, 21 days). Categories: 1.Without itching. 2.Itching.

Measure: Itching scalp

Time: 10 seconds

---

Description: Evaluate the absence or loss of eyelashes, daily in the morning. Categories: 1.Without alterations. 2.White spaces. 3. Fall when exploring.

Measure: Loss of eyelashes

Time: 15 seconds

---

Description: Evaluate the absence or drooping of eyebrows (Daily, morning, 21 days). Categories: 1. Without alterations. 2.White spaces. 3. Fall when exploring.

Measure: Drooping of eyebrows

Time: 10 seconds

---

Description: Evaluate eyelid edema (Daily, morning, 21 days). Categories: 1. Without edema. 2. With edema

Measure: Eyelid edema

Time: 5 seconds

---

Description: Check the vascularity of the sclera (Daily, morning, 21 days). Categories: 1.White sclera. 2.Small blood vessels. 3. Large blood vessels. 4.Hemorrhage.

Measure: Vascularity of the sclera

Time: 10 seconds

---

Description: Assess ocular hydration (Daily, morning, 21 days). Categories: 1.Hydrated. 2.Dry mucus. 3.Absence of tears. 4 sunken eyes

Measure: Ocular hydration

Time: 15 seconds

---

Description: Evaluate sclera color, daily in the morning. Categories: 1.White. 2. Localized yellow. 3.General yellow. 4.Other colors.

Measure: Sclera color

Time: 10 seconds

---

Description: Evaluation of smell, presenting non-irritating odors and ask if it distinguishes them (Daily, morning, 21 days). Categories: 1.Normal. 2. Hyposmia. 3.Anosmia.

Measure: Sense of smell

Time: 30 seconds

---

Description: Evaluate the presence of irritation in the nostrils (Daily, morning, 21 days). Categories: 1.No irritation. 2.With irritation.

Measure: Irritation in the nostrils

Time: 10 seconds

---

Description: Assess nasal secretions (Daily, morning, 21 days). Categories: 1. Absence. 2.Transparent. 3.Of other colors. 4.With blood.

Measure: Nasal secretions

Time: 10 seconds

---

Description: Evaluate the presence of cheilitis (Daily, morning, 21 days). Categories: 1.Without cheilitis. 2.Unilateral. 3.Bilateral. 4.With ulcers.

Measure: Cheilitis

Time: 5 seconds

---

Description: Assess taste buds (Daily, morning, 21 days). Categories: 1. Normal. 2. Inflamed. 3. Painful. 4. Bleeding.

Measure: Taste buds

Time: 10 seconds

---

Description: Evaluate the presence of the saw edge of the tongue (Daily, morning, 21 days). Categories 1.Normal. 2.Flat 3.With serrated edge.

Measure: Saw edge of the tongue

Time: 10 seconds

---

Description: Look for changes in the body of the tongue (Daily, morning, 21 days). Categories: 1.No alterations. 2.Geographic. 3.Fissured.

Measure: Changes in the body of the tongue

Time: 10 seconds

---

Description: Look for changes in the thickness of the tongue (Daily, morning, 21 days). Categories: 1. Normal thickness. 2. Abnormal thickness, swollen.

Measure: Thickness of the tongue

Time: 5 seconds

---

Description: Assess the presence of salivation (Daily, morning, 21 days). Categories: 1.Normal. 2.Excessive salivation. 3 absent.

Measure: Salivation

Time: 10 seconds

---

Description: Evaluate the taste presenting food from their tray and ask if you distinguish the flavors (Daily, morning, 21 days). Categories: 1.Conserved. 2. Hypogeusia. 3.Ageusia.

Measure: Taste

Time: 30 seconds

---

Description: Evaluation of the gums (Daily, morning, 21 days). Categories: 1.Normal. 2.Hypersensitive 3.Inflamed. 4. Bleeding.

Measure: Gums

Time: 10 seconds

---

Description: Evaluation of skin sensitivity (Daily, morning, 21 days). Categories: 1.Normal. 3.Altered sensitivity. 3.Painful.

Measure: Skin sensitivity

Time: 30 seconds

---

Description: Assess the presence of lesions (Daily, morning, 21 days). Categories: 1. No lesions. 2.Dermatitis. 3. Open lesions.

Measure: Skin lesions

Time: 10 seconds

---

Description: Assess skin hydration (Daily, morning, 21 days). Categories: 1.Normal. 2.Fat. 3.Dry.

Measure: Skin hydration

Time: 10 seconds

---

Description: Evaluate skin texture (Daily, morning, 21 days). Categories: 1.Lisa. 2.Rugose. 3.Descamative

Measure: Skin texture

Time: 10 seconds

---

Description: Check for loss or absence of body hair (Daily, morning, 21 days). Categories: 1.Present. 2.Fall. 3.Absence.

Measure: Absence of body hair

Time: 10 seconds

---

Description: Evaluate by finger pressure the 7th cervical hypersensitivity (Every 2 days, morning, 21 days). Categories: 1. It does not cause pain. 2. It causes pain.

Measure: Cervical pain points

Time: 5 seconds

---

Description: Search for hypersensitivity on the inside of the forearm (Every 2 days, morning, 21 days)

Measure: Forearm pain points

Time: 5 seconds

---

Description: Ask if he presents odynophagia (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2. Present.

Measure: Odynophagia

Time: 5 seconds

---

Description: Evaluation of the presence of cough (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2.Productive. 3.Dry

Measure: Cough

Time: 5 seconds.

---

Description: Evaluation of the presence of sneezing (Daily, 2 shifts, 21 days). Categories: 1. Absent. 2. Present.

Measure: Sneezing

Time: 5 seconds

---

Description: Respiration rhythm evaluation (Daily, 2 shifts, 21 days). Categories: 1. Normal. 2.Altered.

Measure: Respiration rhythm

Time: 1 minute

---

Description: Assessment of abdominal breathing (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2. Present.

Measure: Abdominal breathing

Time: 20 seconds

---

Description: Evaluation of the use of accessory muscles when breathing (Daily, 2 shifts, 21 days). Categories: 1.Absent. 2. Present.

Measure: Use of accessory muscles when breathing

Time: 10 seconds

---

Description: Evaluate the presence of xiphoid retraction when breathing (Daily, 2 shifts, 21 days). Categories: 1. Absent. 2. Present.

Measure: Xiphoid retraction when breathing

Time: 10 seconds

---

Description: Assess the presence and degree of dyspnea (Daily, 2 shifts, 21 days). Categories: 1.Without difficulty. 2.When standing. 3.When sitting. 2.When speaking, 3.Lying down.

Measure: Dyspnea

Time: 10 seconds

---

Description: Evaluate the abdomino-cutaneous reflexes (Diary, verpertino, 21 days). Categories: 1. Present. 2. Absent

Measure: Abdomino-cutaneous reflexes

Time: 20 seconds

---

Description: Assess rebound sensitivity (Daily, verpertino, 21 days). Categories: 1. Without sensitivity. 2. With sensitivity.

Measure: Rebound sensitivity

Time: 15 seconds

---

Description: Evaluate the presence of pain in the right hypochondrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Measure: Right hypochondrium

Time: 5 seconds

---

Description: Evaluate the presence of pain in the epigastrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Measure: Epigastrium

Time: 5 seconds

---

Description: Evaluate the presence of pain in the left hypochondrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Measure: Left hypochondrium

Time: 5 seconds

---

Description: Assess the presence of pain in the right flank. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Measure: Right flank

Time: 5 seconds

---

Description: Assess the presence of pain in the mesogastrium (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Measure: Mesogastrium

Time: 5 seconds

---

Description: Evaluate the presence of pain in the left flank. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Measure: Left flank

Time: 5 seconds

---

Description: Evaluate the presence of pain in the right iliac fossa. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Measure: Right iliac fossa.

Time: 5 seconds

---

Description: Evaluate the presence of pain in the hypogastrium. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Measure: Hypogastrium

Time: 5 seconds

---

Description: Assess the presence of pain in the left iliac fossa. (Daily, evening, 21 days) Categories: 1. No pain. 2. With pain.

Measure: Left iliac fossa.

Time: 5 seconds

---

Description: Ask for the presence of vomiting in 24 hours (Daily, evening, 21 days). Categories: 1. Absent. 2. Present.

Measure: Vomiting

Time: 5 seconds

---

Description: Ask about the presence of appetite (Daily, evening, 21 days). Categories: 1. Increased appetite. 2.Normal 3.Hypoexia. 4.Anorexia.

Measure: Appetite

Time: 5 seconds

---

Description: Ask about the presence of reflux (Daily, evening 21 days). Categories: 1. Absent. 2. After eating (specify food). 3. At bedtime. 4. Sudden

Measure: Reflux

Time: 5 seconds

---

Description: Ask about the presence of more common burps than normal (Daily, evening, 21 days). Categories: 1.Normales 2. Augmented.

Measure: Burps

Time: 5 seconds

---

Description: Evaluation of defecation by means of bowel movements with the Bristol scale (Daily, evening, 21 days). Categories: 1.Normal (T3, T4) 2.Constipation (T1, T2). 3. Diarrhea (T5, T6, T7).

Measure: Bristol scale

Time: 10 seconds

---

Description: Evaluation of hair loss on legs (Every 2 days, evening, 21 days) Categories: 1. Without alterations. 2.White spaces. 3. Fall when exploring.

Measure: Hair loss on legs

Time: 10 seconds

---

Description: Evaluation of the sensitivity of the tibial tract (Every 2 days, evening, 21 days) Categories: 1. No pain. 2.Painful.

Measure: Sensitivity of the tibial tract

Time: 10 seconds

---

Description: Assessment of nail strength (Every 2 days, evening, 21 days). Categories: 1. Strong. 2. Brittle. 3.Not assessable.

Measure: Nail strength

Time: 10 seconds

---

Description: Check the presence of fungus in the nails of the hands (Every 2 days, evening, 21 days). Categories: 1. Absent. 2. Present. 3.Not assessable.

Measure: Fungus in the nails of the hands

Time: 10 seconds

---

Description: Look for the presence of white stripes on the nails (Every 2 days, evening, 21 days). Categories: 1. Absent. 2. Present. 3.Not assessable.

Measure: White stripes on the nails

Time: 5 seconds

---

Description: Look for the presence of white spots on the nails (Every 2 days, evening, 21 days). Categories: 1. Absent. 2. Present. 3.Not assessable.

Measure: White spots on the nails

Time: 5 seconds

---

Description: Look for the presence of ridges on the nails (Every 2 days, evening, 21 days). Categories: 1.Lisas. 2.With ridges. 3.Not assessable.

Measure: Ridges on the nails

Time: 5 seconds

---

Description: Taking the height (at the beginning of the protocol). Measure in cm.

Measure: Height

Time: 1 minute

---

Description: Weight taking (Every 2 days, 2 hours after breakfast, for 21 days). Measured in kg.

Measure: Weight

Time: 1 minute

---

Description: Calculation of BMI (Every 2 days, morning, for 21 days). Measured in kg / m2.

Measure: BMI

Time: 30 seconds

---

Description: Measurement by blood sample of erythrocytes (Every 3 days, for 21 days). Measured at 10 ^ 6 / uL.

Measure: Erythrocytes

Time: 20 seconds

---

Description: Measurement by blood sample of hemoglobin (Every 3 days, for 21 days). Measured in g / dL.

Measure: Hemoglobin

Time: 20 seconds

---

Description: Measurement by blood sample of hematocrit (Every 3 days, for 21 days). Measurement in %.

Measure: Hematocrit

Time: 20 seconds

---

Description: Measurement by blood sample of mean corpuscular volume (MCV) (Every 3 days, for 21 days). Measured in fL.

Measure: Mean corpuscular volume

Time: 20 seconds

---

Description: Measurement by blood sample of mean hemoglobin concentration (Every 3 days, for 21 days). Measurement in pg.

Measure: Mean hemoglobin concentration

Time: 20 seconds

---

Description: Measurement every 3 days by blood sample of mean corpuscular hemoglobin concentration (Every 3 days, for 21 days). Measured in g / dL

Measure: Mean corpuscular hemoglobin concentration

Time: 20 seconds

---

Description: Erythrocyte distribution width measurement by blood sample (Every 3 days, for 21 days). Measured in%.

Measure: Erythrocyte distribution width

Time: 20 seconds

---

Description: Measurement by blood sample of the hemoglobin distribution index (Every 3 days, for 21 days). Measured in g / dL.

Measure: Hemoglobin distribution index

Time: 20 seconds

---

Description: Measurement by blood sample of leukocytes (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Measure: Leukocytes

Time: 20 seconds

---

Description: Measurement by blood sample of neutrophils (%) (Every 3 days, for 21 days). Measurement in%

Measure: Neutrophils (%)

Time: 20 seconds

---

Description: Measurement by blood sample of neutrophils (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Measure: Neutrophils (#)

Time: 20 seconds

---

Description: Measurement by blood sample of lymphocytes (%) (Every 3 days, for 21 days). Measurement in%

Measure: Lymphocytes (%)

Time: 20 seconds

---

Description: Measurement by blood sample of lymphocytes (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Measure: Lymphocytes (#)

Time: 20 seconds

---

Description: Measurement by blood sample of monocytes (%) (Every 3 days, for 21 days). Measurement in%

Measure: Monocytes (%)

Time: 20 seconds

---

Description: Measurement by blood sample of monocytes (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Measure: Monocytes (#)

Time: 20 seconds

---

Description: Measurement by blood sample of eosinophils (%) (Every 3 days, for 21 days). Measurement in%

Measure: Eosinophils (%)

Time: 20 seconds

---

Description: Measurement by blood sample of eosinophils (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Measure: Eosinophils (#)

Time: 20 seconds

---

Description: Measurement by blood sample of basophils (%) (Every 3 days, for 21 days). Measurement in%

Measure: Basophils (%)

Time: 20 seconds

---

Description: Measurement by blood sample of basophils (#) (Every 3 days, for 21 days). Measured in 10 ^ 3 / μL

Measure: Basophils (#)

Time: 20 seconds

---

Description: Measurement of prothrombin time (PT) by blood sample (Every 3 days, for 21 days). Measure in seconds

Measure: Prothrombin time

Time: 20 seconds

---

Description: Measurement by blood sample of INR (Every 3 days, for 21 days). Measure in units

Measure: INR

Time: 20 seconds

---

Description: Measurement by control blood sample (100-50) (Every 3 days, for 21 days). Measure in seconds

Measure: Control blood sample (100-50) 1

Time: 20 seconds

---

Description: Measurement by blood sample of partial thromboplastin time (Every 3 days, for 21 days). Measure in seconds

Measure: Partial thromboplastin time

Time: 20 seconds

---

Description: Measurement by control blood sample (100-50) (Every 3 days, for 21 days). Measure in seconds

Measure: Control blood sample (100-50) 2

Time: 20 seconds

---

Description: Measurement by blood sample of platelets. Measured in 10 ^ 3 / μL

Measure: Platelets

Time: 20 seconds

---

Description: Measurement by blood sample of mean platelet volume (MPV) (Every 3 days, for 21 days). Measured in fL.

Measure: Mean platelet volume

Time: 20 seconds

---

Description: Initial screening test to diagnose patients with signs or symptoms suggestive of venous thromboembolism, it is a marker of endogenous fibrinolysis. Measurement by blood sample of dimer D (Every 3 days, for 21 days). Measured in ng / mL

Measure: D-dimer

Time: 20 seconds

---

Description: Sulfur amino acid that originates in the metabolism of methionine, and is very aggressive for the arterial endothelium. Measurement by blood sample of homocysteine levels (Every 3 days, for 21 days). Measured in µmol / l.

Measure: Homocysteine

Time: 20 seconds

---

Description: Fat-soluble vitamin involved in calcium homeostasis and bone metabolism, regulation of genes involved in the regulation of cell proliferation, cell differentiation and apoptosis. It has been suggested that it exerts immunomodulatory and antiproliferative effects. Measurement by blood sample of levels of 25-hydroxycholecalciferol (Every 3 days, for 21 days). Measured in nmol / L

Measure: Vitamin D

Time: 20 seconds

---

Description: Measurement by blood sample of calcium (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Calcium

Time: 20 seconds

---

Description: Measurement by blood sample of phosphorus (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Phosphorus

Time: 20 seconds

---

Description: Measurement by blood sample of magnesium (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Magnesium

Time: 20 seconds

---

Description: Measurement by blood sample of sodium (Every 3 days, for 21 days). Measured in mmol / L.

Measure: Sodium

Time: 20 seconds

---

Description: Measurement by blood sample of potassium (Every 3 days, for 21 days). Measured in mmol / L.

Measure: Potassium

Time: 20 seconds

---

Description: Measurement by blood sample of chlorine (Every 3 days, for 21 days). Measured in mmol / L.

Measure: Chlorine

Time: 20 seconds

---

Description: A measure of the concentration of free glucose in the blood, serum or blood plasma. Measured in mg / dL.

Measure: Blood glucose

Time: 20 seconds

---

Description: Taking a blood sample of total cholesterol (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Total cholesterol

Time: 20 seconds

---

Description: Taking a blood sample of triglycerides (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Triglycerides

Time: 20 seconds

---

Description: Taking a blood sample of LDL cholesterol (Every 3 days, for 21 days). Measured in mg / dL.

Measure: LDL cholesterol

Time: 20 seconds

---

Description: Taking a blood sample for HDL cholesterol (Every 3 days, for 21 days). Measured in mg / dL.

Measure: HDL cholesterol

Time: 20 seconds

---

Description: Taking a blood sample to evaluate the level of aspartate aminotransferase (Every 3 days, for 21 days). Measured in U / L.

Measure: Aspartate aminotransferase

Time: 20 seconds

---

Description: Taking a blood sample to evaluate the level of alanine aminotransferase (Every 3 days, for 21 days). Measured in U / L.

Measure: Alanine aminotransferase

Time: 20 seconds

---

Description: Taking a blood sample to evaluate the total bilirubin level (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Total bilirubin

Time: 20 seconds

---

Description: Taking a blood sample to evaluate the level of direct bilirubin (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Direct bilirubin

Time: 20 seconds

---

Description: Taking a blood sample to evaluate the level of indirect bilirubin (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Indirect bilirubin

Time: 20 seconds

---

Description: Taking a blood sample to evaluate the level of alkaline phosphatase (Every 3 days, for 21 days). Measured in U / L.

Measure: Alkaline phosphatase

Time: 20 seconds

---

Description: Taking a blood sample to evaluate the level of total proteins (Every 3 days, for 21 days). Measured in g / dL.

Measure: Total proteins

Time: 20 seconds

---

Description: Taking a blood sample to evaluate the albumin level (Every 3 days, for 21 days). Measured in g / dL.

Measure: Albumin level

Time: 20 seconds

---

Description: Taking a blood sample to evaluate the globulin level (Every 3 days, for 21 days). Measured in g / dL.

Measure: Globulin level

Time: 20 seconds

---

Description: Taking a blood sample to evaluate the A / G ratio (Every 3 days, for 21 days). Measured in g / dL.

Measure: A / G ratio

Time: 20 seconds

---

Description: ake a blood sample to evaluate the levels of urea nitrogen (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Urea nitrogen

Time: 20 seconds

---

Description: Take a blood sample to evaluate urea levels (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Urea

Time: 20 seconds

---

Description: Take a blood sample to evaluate creatitine levels (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Creatitine

Time: 20 seconds

---

Description: Take a blood sample to evaluate uric acid levels (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Uric acid

Time: 20 seconds

---

Description: Take a blood sample to evaluate ferritin levels (Every 3 days, for 21 days). Measured in ng/mL.

Measure: Ferritin

Time: 20 seconds

---

Description: Take a blood sample to evaluate fibrinogen levels (Every 3 days, for 21 days). Measured in mg / dL.

Measure: Fibrinogen

Time: 20 seconds

---

Description: Take a blood sample to evaluate the levels of C-reactive protein (Every 3 days, for 21 days). Measured in mg/L.

Measure: C-reactive protein

Time: 20 seconds

---

Description: Use of the appropriate procedures established in the NSS indications (Specific supplementation scheme, based on 1 sachet, intramuscular B vitamins and probiotics). Quantification of empty supplement envelopes (Daily, 2 shifts, 21 days). Categories: 1.On empty. 2. About half. 3.Full.

Measure: Adherence to the Nutritional Support System (NSS)

Time: 5 seconds

---

Description: Quantification of the time from when the envelope is added in water, until everything is consumed (Daily, 2 shifts, 21 days). Categories: 1. Less than 15 minutes. 2. More than 15 minutes.

Measure: Intake time

Time: 15 minutes

---

Description: Quantification of the amount of prepared "NSS" he drink (Daily, 2 shifts, 21 days). Categories: 1.All the preparation. 2.Half. 3.Nothing.

Measure: Amount of prepared "NSS" he drink

Time: 15 minutes

---

Description: In-person verification of the taking of the floratil pill and observe that they do not vomit it (Daily, 2 shifts, first 6 days). Categories: 1. The pill is taken. 2.The pill is not taken.

Measure: Taking of the "floratil" pill

Time: 20 seconds

---

Description: Corroborate in person the correct application of the neurobion injection (Daily, evening, first 5 days). Categories: 1. It applies. 2.Not applicable.

Measure: Neurobion injection

Time: 1 minute

---

Description: Unit of thermal energy, which is equal to the amount of heat needed to raise the temperature of 1 gram of water by 1 degree Celsius. Unit of measurement of the energy content of food that consists of the number of calories that a given weight of food can develop in the tissues, or in the physical work equivalent to them. Calculate the grams that the food has of each macronutrient and multiply it by the energy intake. Based on the Mexican Equivalent Food System. Number in Kcal.

Measure: Diet calories

Time: 15 minutes

---

Description: Evaluate the amount of trans fat in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Measure: Trans fat in the diet

Time: 2 minutes

---

Description: Evaluate the amount of saturated fat in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Measure: Saturated fat in the diet.

Time: 2 minutes

---

Description: Evaluate the amount of monounsaturated fats in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Measure: Monounsaturated fats in the diet

Time: 2 minutes

---

Description: Evaluate the amount of polyunsaturated fat in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Measure: Polyunsaturated fat in the diet

Time: 2 minutes

---

Description: Evaluate the amount of protein of animal origin in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Measure: Protein of animal origin in the diet

Time: 2 minutes

---

Description: Evaluate the amount of plant-based protein in the diet. (Daily, 2 shifts, 21 days). Based on the Mexican Equivalent Food System. Number in g.

Measure: Plant-based protein in the diet

Time: 2 minutes

---

Description: Accurate record of the amount of fluids administered. Evaluate the income of 24 hrs. (Daily, 2 shifts, 21 days). Number in ml.

Measure: Fluid balance (income)

Time: 5 minutes

---

Description: Accurate record of the amount of liquids eliminated by any means. Evaluate the expenses of 24 hrs. (Daily, 2 shifts, 21 days). Number in ml.

Measure: Fluid balance (outcome)

Time: 5 minutes

---

Description: Need or desire to eat. Observe the percentage of the tray with food that was ingested (Daily, 2 shifts, 21 days). Categories: 1. 100% ingested. 2.75%. 3.50%. 4.25%.

Measure: Hungry

Time: 15 seconds

---

Description: Cardiovascular disease risk indicator. Measure with a tape measure with the patient standing, feet together, arms at the sides and the abdomen relaxed, encircling the abdomen at the level of the navel at the midpoint between the last rib and the iliac crest and without pressing, taking an inspiration deep, taking the measurement at the moment of expelling the air.

Measure: Abdominal circumference

Time: 1 minute

---

Description: It is used to know the nutritional status of the patient. It is obtained by measuring the middle part of the arm with a tape measure, taking as a reference the length between the point of the shoulder (acromion) and the head of the radius (olecranon). Take the circumference of the arm using a tape measure (every 2 days, 2 hours after breakfast, in the morning, for 21 days). Measure in mm.

Measure: Arm circumference.

Time: 3 minutes

---

Description: It is measured on the midline of the back of the arm (triceps) at 1 cm from the height of the midpoint of the arm. Taking triceps fold measuring tape and caliper (every 2 days, 2 hours after breakfast, morning, for 21 days)). Measure in mm.

Measure: Tricipital fold

Time: 3 minutes

---

Description: Calculation from arm circumference and triceps fold. Calculate it according to the formula proposed by Frisancho. (every 2 days, 2 hours after breakfast, morning, for 21 days). Measure in mm2.

Measure: Arm area

Time: 1 minute

---

Description: Set of peculiarities that characterize the individuals of a species, dividing them into male and female, and make possible a reproduction characterized by genetic diversification. Based on an official ID. Categories: 1. Male 2. Female

Measure: Biological sex

Time: 30 seconds

---

Description: Time elapsed from the birth of a living being to the moment the calculation is made. Based on an official ID. Number between 30 and 75.

Measure: Age

Time: 30 seconds

---

Description: Sugars attached to the surface of red blood cells, and according to their composition. Evaluate by blood sample. Categories: 1.A, 2. B, 3.AB 4.O.

Measure: AB0 system

Time: 2 minutes

---

Description: Protein in red blood cells or erythrocytes. Obtaining by blood sample. Categories: 1.Rh (+) 2.Rh (-).

Measure: Rh factor

Time: 2 minutes

---

Secondary Outcomes

Description: Record the use of proton pump inhibitors (omeprazole, pantoprazole) (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

Measure: Use of proton pump inhibitors

Time: 5 seconds

---

Description: Record the use of obesity medications (orlistat, acarbose, bile acid sequestrants, etc.) (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

Measure: Obesity medications

Time: 5 seconds

---

Description: Record the use of antiepileptic drugs (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

Measure: Use of antiepileptic drugs

Time: 5 seconds

---

Description: Record the use of oral contraceptives (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

Measure: Use of oral contraceptives

Time: 5 seconds

---

Description: Record the use of antimitotics (colchicine) (daily, evening, for 21 days). Categories: 1.Not prescribed. 2.Prescribed.

Measure: Use of antimitotics

Time: 5 seconds

---

Description: Chemical substance that kills or prevents the growth of certain classes of sensitive microorganisms. Record the antibiotics that are being administered. (daily, evening, for 21 days) Categories: 1.Not used. 2.Use of antibiotics (specify which)

Measure: Antibiotics

Time: 5 seconds

---

Description: Medicines whose main pharmacological effect is to relieve pain. Record the analgesics that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of analgesics (specify which)

Measure: Analgesics

Time: 5 seconds

---

Description: Drugs with anti-inflammatory and immunosuppressive effect. Record the corticosteroids that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of corticosteroids (specify which).

Measure: Corticosteroids

Time: 5 seconds

---

Description: Substance that causes the elimination of water and electrolytes from the body through urine. Record the diuretics that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of diuretics (specify which)

Measure: Diuretics

Time: 5 seconds

---

Description: Drugs used to lower blood pressure. Record the antihypertensive drugs that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of antihypertensives (specify which)

Measure: Antihypertensive

Time: 5 seconds

---

Description: Endogenous or exogenous substance that interferes with or inhibits blood clotting, creating an antithrombotic or prohemorrhagic state. Record the anticoagulants that are being administered (daily, evening, for 21 days). Categories: 1.Not used. 2.Use of anticoagulants (specify which)

Measure: Anticoagulants

Time: 5 seconds

---

Description: Medications that attend to a basic pathology and have not been considered in the previous variables. Record the medications that are being administered and have not been named before (daily, evening, for 21 days). Write the medications.

Measure: Other medications

Time: 5 seconds

---

Description: Disturbance of the normal state of the level of absorption acutely due to a pathological alteration. Record the acute alterations that affect the absorption of nutrients (daily, evening, for 21 days). Categories: 1.None. 2.Intolerance. 3. Allergies 4. Diarrhea 5. Infection or inflammation in any organ of the digestive system.

Measure: Acute alterations in the absorption of nutrients.

Time: 5 seconds

---

Description: Any alteration in the response to the action of the drug due to the concomitant reaction of another chemical substance. Side effects reported through the clinic and laboratory (daily, evening, for 21 days). Categories: 1.None. 2.Rash. 3.Head or dizziness. 4.Gastrointestinal pain. 5.Other (specify).

Measure: Drug interactions and adverse effects

Time: 5 seconds

---

Description: Artificial supply of oxygen (O2) in the inspired air; its main objective is tissue oxygenation. Check the quantity of liters that you have pre-written for 24 hours (daily, evening, for 21 days). Number of liters.

Measure: Oxygen therapy

Time: 5 seconds

---

Description: Attitude or disposition in emotional life. It is not a transitory emotional situation. It is a state, a way of staying, of being, whose duration is prolonged and fades over the rest of the psychic world. Assess the patient's state of mind (daily, evening, for 21 days). Categories: 1.Happy. 2.Relaxed. 3. Alert. 4. Annoying 5. Sad. 6.Tense. 7.Tired. 8.Depressed

Measure: Mood

Time: 5 seconds

---

HP:0000822: Hypertension

Genes 411

PLIN1 SMARCAL1 LIMK1 SDCCAG8 ELP1 TSC2 FMR1 CPOX GNAS COX1 SH2B3 LYZ CLCN2 NF1 NOTCH3 ARL6 EDA2R ELN APOA1 CTLA4 CC2D2A MLX FGFR2 ADA2 TRNC MMP14 MTRR BANF1 GLA TRNK TRNL1 CCR6 GPC3 CYP11B2 ERCC8 TRIM32 CFH ACVRL1 COL3A1 LRP6 TRNK XYLT2 CFI CALR ITGA8 SLC37A4 SUGCT GBA NF1 CD46 WT1 WRN KLHL3 BBS4 THPO SDHA POU6F2 ABCG8 CORIN NFIX PDE8B NOD2 ARVCF INVS PRKAR1A RET GLA SLC25A11 SCNN1A TRIM28 TRNQ OFD1 B2M WT1 TNFRSF11B ARMC5 FGFR2 HLA-DPB1 PPARG EDA TP53 BNC2 ALX4 LMX1B NPHP1 ACAT1 ACTA2 GNAS GTF2IRD1 SDHC UFD1 ENPP1 GATA5 LEMD3 MYH11 HGD SDHD RET RFC2 IRF5 KCNJ5 LDLR ERCC6 DLST REST CAV1 GANAB BBS10 SMAD3 TET2 TRNW MUC1 POU3F4 OFD1 ADA2 SDHB ERCC4 BBS9 CD2AP LMNA CYP11B1 MEF2A MMP2 CLIP2 COL4A3 ELN COMT HPSE2 BBS2 XYLT1 PRKACA JMJD1C SMAD4 VANGL1 G6PC WNK4 DIS3L2 TMEM70 HBB ENPP1 MAFB LZTFL1 TRNS2 PKD2 USP8 HIRA TRIP13 DNAJB11 FBN1 TGFBR1 CFHR1 SH2B3 PKD1 LMNA PRKAR1A SDHB SCN2B PRTN3 NR3C2 WDR35 MDH2 DNMT3A ELP1 ALMS1 ELN TRNL1 IQCB1 RET MKKS YY1AP1 LARS2 AIP TBX1 TGFBR2 SPRY2 FBN1 NOTCH1 ABCB6 PRKACA MTTP MYLK ARL6 ABCC6 TRAF3IP1 COL5A2 RET STOX1 H19 LEMD3 FGA TMEM67 SEC24C MAX CYP11B1 SLC25A11 ND6 KIF1B ACTN4 ADA2 HSD11B2 DYRK1B NPHP1 BMPR2 PDE3A ND1 TTC8 JAK2 MGP NOTCH2 VHL SDHB SDHAF2 VHL MYMK NPHP3 ABCC6 TGFBR3 PPARG ALMS1 SMAD6 TRPC6 CCDC28B TMEM127 VHL TNFRSF11A SCNN1B BBS5 SCNN1B ARHGAP31 APOB SDHD SDHD PDE3A GDNF RREB1 CYP11B1 ECE1 TMEM237 TRNE SDHC FH YY1AP1 LMNA TGFB2 COX3 GPR101 CYP17A1 BRCA2 THBD LMX1B WNK1 LRIG2 FIG4 CEP290 HLA-DRB1 XPNPEP3 CCND1 MKS1 ACTA2 FUZ COL4A3 CYTB SMAD4 LMNA TRNV SLC2A10 FBN1 PRKG1 COQ7 MLXIPL KIF1B AIP FLT1 SERPINA6 CFB PLIN1 HLA-B NKX2-5 WT1 PKD1 EGFR MC4R EPAS1 SLC2A10 GCH1 BAZ1B NSMCE2 VHL PCSK9 KRT8 WT1 WDPCP TRNK PKD2 APRT HLA-DPA1 MPL COL4A5 KCTD1 SDHD TRIM28 GP1BB THSD1 BBS12 CEP290 FMO3 CYP21A2 CUL3 NPHP4 PKHD1 BICC1 COL4A4 BSCL2 NR3C1 WT1 GANAB C3 COX2 TRNF IFT27 GTF2I STAT1 SDCCAG8 PAM16 MFAP5 LOX IL12B SLC37A4 LDLRAP1 MYH7 BBS7 TGFB3 CBS ARMC5 CEP164 ADAMTSL4 INVS CDH23 COL5A1 CACNA1D LMNA PTPN22 SCNN1A SDHB ABCG5 TBX1 FN1 TMEM127 BBS1 CYP17A1 FN1 RPGRIP1L AIP PHF21A CACNA1H POR ND5 ENG BBS1 PDE11A EXT2 COL1A1 GUCY1A1 TSC1 FBN1 TBL2 HMBS HMBS C8ORF37 NR3C1 FOXF1 PRKAR1A NPHP1 CEP19 KRT18 MAX ABCC6 VAC14 KIF1B KCTD1 TRNS1 HSD11B2 GJA1 SCNN1G KCNJ5 BBIP1 PDE11A ANGPTL6 CDH23 KCNJ5 MAT2A SMAD4 IDUA IFT172 CACNA1D WDR19 ZMPSTE24 CYP11B1 FOXE3 CCN2 GNAS SCNN1G GUCY1A1 NFU1 VHL USP8 CFHR3 NOS3 COL3A1 JAK2 OSGEP

Protein Mutations 18

A1166C A118G C282Y C344T C677T D565H E298D G1051A G1691A G20210A G308A G3514C G389R H295R M235T S49G T393C V617F

SNP 9

rs1017783 rs10177833 rs13333226 rs1801133 rs2398162 rs2540923 rs254093 rs5068 rs7571842